A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2017
At a glance
- Drugs RG 7800 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Acronyms MOONFISH
- Sponsors Roche
- 23 Dec 2016 This trial has been completed in Spain (end date: 12 Dec 2016).
- 20 Dec 2016 Status changed from suspended to discontinued due to unexpected toxicology, Dosing was suspended, the study was put on hold and eventually terminated..
- 08 Dec 2015 Status changed from recruiting to suspended, according to United Kingdom Clinical Research Network record.